November 07, 2025 (MLN):  Macter International Limited (PSX: MACTER) has introduced Semaglutide in Pre-Filled Syringe (PFS) and Pre-Filled Multi-Dose Pen (PFP) presentations, according to a company filing on the Pakistan Stock Exchange (PSX).

Semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, is a modern therapy used globally for the management of Type 2 Diabetes Mellitus and increasingly recognized for its role in weight management and metabolic health.

With this introduction, Macter has become the only company in Pakistan to offer Semaglutide in all three biotechnology dosage formats, Vials, Pre-Filled Syringes, and Pre-Filled Pens.

The company stated that this milestone represents a significant advancement in its Biotech portfolio and reinforces its leadership in introducing advanced and globally competitive therapies to patients in Pakistan.